Pregnancy imposes predictable physiological changes that alter drug absorption, distribution, metabolism, and excretion, shifting both maternal exposure and fetal risk. These changes are clinically important because they can reduce drug concentrations below therapeutic thresholds or, conversely, increase exposure and toxicity as physiology returns toward the nonpregnant state after delivery. The American College of Obstetricians and Gynecologists Committee on Obstetric Practice recommends individualized dosing and closer monitoring because standard regimens often do not account for these dynamics.
Physiological drivers of pharmacokinetic change
During pregnancy blood volume and cardiac output increase substantially, expanding the volume of distribution for hydrophilic drugs and often lowering peak plasma concentrations. Plasma albumin falls, increasing the free fraction of highly protein-bound drugs and altering tissue exposure. Gastrointestinal motility slows and gastric pH rises, which can modestly change oral absorption for certain molecules. Renal blood flow and glomerular filtration rate rise, frequently accelerating renal clearance of renally eliminated drugs. Hepatic enzyme activity shifts in enzyme-specific directions: cytochrome P450 3A4 and 2D6 activities generally increase while CYP1A2 and CYP2C19 activities decline, producing drug- and enzyme-specific changes in metabolic clearance.
Clinical consequences and practical relevance
The net effect is drug-specific. For drugs cleared primarily by the kidney, like some antibiotics and lithium, increased clearance can require higher or more frequent dosing to maintain efficacy. For drugs metabolized by enzymes induced in pregnancy, such as certain opioids and antidepressants, maternal exposure may fall and symptom control can worsen. Conversely, when pregnancy resolves, return of renal and hepatic function can raise plasma levels rapidly, risking toxicity if doses are not reduced. Lamotrigine is a frequently cited example where clearance increases during pregnancy and clinicians often increase doses to prevent seizures; close postpartum reduction prevents overdose. The U.S. Food and Drug Administration guidance on studying medications in pregnancy highlights the need for pregnancy-specific pharmacokinetic data to inform these adjustments.
Beyond pharmacology, social and territorial factors matter: limited access to therapeutic drug monitoring in low-resource settings increases the risk of subtherapeutic treatment or toxicity. Cultural concerns and historical exclusion of pregnant people from clinical trials further limit evidence, making reliance on physiologic principles, close clinical monitoring, and coordination with specialists essential to balancing maternal benefit and fetal safety. Trimester-specificity and individualized care remain central to responsible prescribing in pregnancy.